Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin

HEPATITIS B VACCINE
Brand Name: Energix B, Recombivax HB
Generic Name: Hepatitis B Vaccine
Drug Class: Vaccines, Inactivated, Viral
MOA: Suspension of inactivated and purified hepatitis B surface antigen (HBsAg) derived from human plasma of screened
asymptomatic HBsAg-positive carriers of hepatitis B virus. Hepatitis B vaccine recombinant is the first vaccine produced by gene
splicing. No human plasma is used in its production
 Transmission during birth from an infected mother to her newborn
 Having unprotected sex with an infected person
Adverse Effects: Mild local tenderness at injection site, local inflammatory reaction (swelling, heat, redness, induration, pain);
fever, malaise, fatigue, headache, dizziness, faintness, leg cramps, myalgia, arthralgia. GI: Nausea, vomiting, diarrhea. Skin:
Rash, urticaria, pruritus.
Nursing Responsibilities:
 Additional doses may be required for individuals with a suppressed immune system.
 Correct cold chain vaccine storage should be ensured.
 The injection site batch number and expiry date should be recorded in the patient record.
 Monitor temperature. Some patients develop a temperature elevation of 38.3° C (101° F) following vaccination that
may last 1 or 2 d.
 Note: The ACIP recommends serologic confirmation of postvaccination immunity in patients undergoing dialysis and
in immunodeficient patients.

Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin

OXYTOCIN
Brand Name: Pitocin, Syntocinon, Syntocinon Nasal Spray
Generic Name: Oxytocin
Drug Class: Hormones and Synthetic Substitutes; Oxytocic
MOA: Synthetic, water-soluble polypeptide consisting of eight amino acids, identical pharmacologically to the oxytocic principle
of posterior pituitary.
Adverse Effects: Body as a Whole: Fetal trauma from too rapid propulsion through pelvis, fetal death, anaphylactic reactions,
postpartum hemorrhage, precordial pain, edema, cyanosis or redness of skin. CV: Fetal bradycardia and arrhythmias, maternal
cardiac arrhythmias, hypertensive episodes, subarachnoid hemorrhage, increased blood flow, fatal afibrinogenemia, ECG
changes, PVCs, cardiovascular spasm and collapse. GI: Neonatal jaundice, maternal nausea, vomiting. Endocrine: ADH effects
leading to severe water intoxication and hyponatremia, hypotension. CNS: Fetal intracranial hemorrhage, anxiety. Respiratory:
Fetal hypoxia, maternal dyspnea. Urogenital: Uterine hypertonicity, tetanic contractions, uterine rupture, pelvic hematoma.
Nursing Responsibilities:
 Start flow charts to record maternal BP and other vital signs, I&O ratio, weight, strength, duration, and frequency of
contractions, as well as fetal heart tone and rate, before instituting treatment.
 Monitor fetal heart rate and maternal BP and pulse at least q15min during infusion period; evaluate tonus of
myometrium during and between contractions and record on flow chart. Report change in rate and rhythm
immediately.
 Stop infusion to prevent fetal anoxia, turn patient on her side, and notify physician if contractions are prolonged
(occurring at less than 2-min intervals) and if monitor records contractions about 50 mm Hg or if contractions last 90
seconds or longer. Stimulation will wane rapidly within 2–3 min. Oxygen administration may be necessary.
 If local or regional (caudal, spinal) anesthesia is being given to the patient receiving oxytocin, be alert to the possibility
of hypertensive crisis (sudden intense occipital headache, palpitation, marked hypertension, stiff neck, nausea,
vomiting, sweating, fever, photophobia, dilated pupils, bradycardia or tachycardia, constricting chest pain).
 Monitor I&O during labor. If patient is receiving drug by prolonged IV infusion, watch for symptoms of water
intoxication (drowsiness, listlessness, headache, confusion, anuria, weight gain). Report changes in alertness and
orientation and changes in I&O ratio (i.e., marked decrease in output with excessive intake).
 Check fundus frequently during the first few postpartum hours and several times daily thereafter.
 Incidence of hypersensitivity or allergic reactions is higher when oxytocin is given by IM or IV injection rather than by
IV infusion (diluted solution).
Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin
Vitamin K
Brand Name: Vitamin K
Generic Name: AquaMEPHYTON, Konakion, Mephyton, Phylloquinone
Drug Class: Hormones and Synthetic Substitutes; Vitamin; Antidote
Adverse Effects: Body as a Whole: Hypersensitivity or anaphylaxis-like reaction: facial flushing, cramp-like pains, convulsive
movements, chills, fever, diaphoresis, weakness, dizziness, shock, cardiac arrest. CNS: Headache (after oral dose), brain
damage, death. GI: Gastric upset. Hematologic: Paradoxic hypoprothrombinemia (patients with severe liver disease), severe
hemolytic anemia. Metabolic: Hyperbilirubinemia, kernicterus. Respiratory: Bronchospasm, dyspnea, sensation of chest
constriction, respiratory arrest. Skin: Pain at injection site, hematoma, and nodule formation, erythematous skin eruptions (with
repeated injections). Special Senses: Peculiar taste sensation.
Nursing Responsibilities:
 Monitor patient constantly. Severe reactions, including fatalities, have occurred during and immediately after IV
injection (see ADVERSE EFFECTS).
 Lab tests: Baseline and frequent PT/INR.
 Frequency, dose, and therapy duration are guided by PT/INR clinical response.
 Monitor therpeutic effectiveness which is indicated by shortened PT, INR, bleeding, and clotting times, as well as
decreased hemorrhagic tendencies.
 Be aware that patients on large doses may develop temporary resistance to coumarin-type anticoagulants. If oral
anticoagulant is reinstituted, larger than former doses may be needed. Some patients may require change to heparin.

Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin

Vitamin K
Brand Name: Vitamin K
Generic Name: AquaMEPHYTON, Konakion, Mephyton, Phylloquinone
Drug Class: Hormones and Synthetic Substitutes; Vitamin; Antidote
Adverse Effects: Body as a Whole: Hypersensitivity or anaphylaxis-like reaction: facial flushing, cramp-like pains, convulsive
movements, chills, fever, diaphoresis, weakness, dizziness, shock, cardiac arrest. CNS: Headache (after oral dose), brain
damage, death. GI: Gastric upset. Hematologic: Paradoxic hypoprothrombinemia (patients with severe liver disease), severe
hemolytic anemia. Metabolic: Hyperbilirubinemia, kernicterus. Respiratory: Bronchospasm, dyspnea, sensation of chest
constriction, respiratory arrest. Skin: Pain at injection site, hematoma, and nodule formation, erythematous skin eruptions
(with repeated injections). Special Senses: Peculiar taste sensation.
Nursing Responsibilities:
 Monitor patient constantly. Severe reactions, including fatalities, have occurred during and immediately after IV
injection (see ADVERSE EFFECTS).
 Lab tests: Baseline and frequent PT/INR.
 Frequency, dose, and therapy duration are guided by PT/INR clinical response.
 Monitor therpeutic effectiveness which is indicated by shortened PT, INR, bleeding, and clotting times, as well as
decreased hemorrhagic tendencies.
 Be aware that patients on large doses may develop temporary resistance to coumarin-type anticoagulants. If oral
anticoagulant is reinstituted, larger than former doses may be needed. Some patients may require change to heparin.
Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin

OXYTOCIN
Brand Name: Pitocin, Syntocinon, Syntocinon Nasal Spray
Generic Name: Oxytocin
Drug Class: Hormones and Synthetic Substitutes; Oxytocic
MOA: Synthetic, water-soluble polypeptide consisting of eight amino acids, identical pharmacologically to the oxytocic principle
of posterior pituitary.
Adverse Effects: Body as a Whole: Fetal trauma from too rapid propulsion through pelvis, fetal death, anaphylactic reactions,
postpartum hemorrhage, precordial pain, edema, cyanosis or redness of skin. CV: Fetal bradycardia and arrhythmias, maternal
cardiac arrhythmias, hypertensive episodes, subarachnoid hemorrhage, increased blood flow, fatal afibrinogenemia, ECG
changes, PVCs, cardiovascular spasm and collapse. GI: Neonatal jaundice, maternal nausea, vomiting. Endocrine: ADH effects
leading to severe water intoxication and hyponatremia, hypotension. CNS: Fetal intracranial hemorrhage, anxiety. Respiratory:
Fetal hypoxia, maternal dyspnea. Urogenital: Uterine hypertonicity, tetanic contractions, uterine rupture, pelvic hematoma.
Nursing Responsibilities:
 Start flow charts to record maternal BP and other vital signs, I&O ratio, weight, strength, duration, and frequency of
contractions, as well as fetal heart tone and rate, before instituting treatment.
 Monitor fetal heart rate and maternal BP and pulse at least q15min during infusion period; evaluate tonus of
myometrium during and between contractions and record on flow chart. Report change in rate and rhythm
immediately.
 Stop infusion to prevent fetal anoxia, turn patient on her side, and notify physician if contractions are prolonged
(occurring at less than 2-min intervals) and if monitor records contractions about 50 mm Hg or if contractions last 90
seconds or longer. Stimulation will wane rapidly within 2–3 min. Oxygen administration may be necessary.
 If local or regional (caudal, spinal) anesthesia is being given to the patient receiving oxytocin, be alert to the possibility
of hypertensive crisis (sudden intense occipital headache, palpitation, marked hypertension, stiff neck, nausea,
vomiting, sweating, fever, photophobia, dilated pupils, bradycardia or tachycardia, constricting chest pain).
 Monitor I&O during labor. If patient is receiving drug by prolonged IV infusion, watch for symptoms of water
intoxication (drowsiness, listlessness, headache, confusion, anuria, weight gain). Report changes in alertness and
orientation and changes in I&O ratio (i.e., marked decrease in output with excessive intake).
 Check fundus frequently during the first few postpartum hours and several times daily thereafter.
 Incidence of hypersensitivity or allergic reactions is higher when oxytocin is given by IM or IV injection rather than by
IV infusion (diluted solution).

Student’s name: Jade Gordoncillo Level: II Section: B2- Agustin

HEPATITIS B VACCINE
Brand Name: Energix B, Recombivax HB
Generic Name: Hepatitis B Vaccine
Drug Class: Vaccines, Inactivated, Viral
MOA: Suspension of inactivated and purified hepatitis B surface antigen (HBsAg) derived from human plasma of screened
asymptomatic HBsAg-positive carriers of hepatitis B virus. Hepatitis B vaccine recombinant is the first vaccine produced by gene
splicing. No human plasma is used in its production
 Transmission during birth from an infected mother to her newborn
 Having unprotected sex with an infected person
Adverse Effects: Mild local tenderness at injection site, local inflammatory reaction (swelling, heat, redness, induration, pain);
fever, malaise, fatigue, headache, dizziness, faintness, leg cramps, myalgia, arthralgia. GI: Nausea, vomiting, diarrhea. Skin:
Rash, urticaria, pruritus.
Nursing Responsibilities:
 Additional doses may be required for individuals with a suppressed immune system.
 Correct cold chain vaccine storage should be ensured.
 The injection site batch number and expiry date should be recorded in the patient record.
 Monitor temperature. Some patients develop a temperature elevation of 38.3° C (101° F) following vaccination that
may last 1 or 2 d.
 Note: The ACIP recommends serologic confirmation of postvaccination immunity in patients undergoing dialysis and
in immunodeficient patients.